We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

PTAB Upholds Pozen Patent In Kyle Bass Challenge

Law360, New York (February 22, 2017, 4:55 PM EST) -- The Patent Trial and Appeal Board on Tuesday upheld the validity of a patent on Pozen Inc.’s arthritis and ulcer drug Vimovo in an inter partes review requested by the Coalition for Affordable Drugs, an organization started by hedge fund manager Kyle Bass.

In a final decision, the PTAB said the coalition failed to show that Pozen’s patent would have been obvious at the time of the invention. The patent covers a method of treating patients at risk of developing an ulcer due to the use...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.